Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): A double-blind, randomised controlled trial

The Lancet

Volumn 387, Issue 10021, 2016, Pages 866-873

  Forbes, John F ^a   Sestak, Ivana ^b   Howell, Anthony ^c   Bonanni, Bernardo ^d   Bundred, Nigel ^e   Levy, Christelle ^f   Von Minckwitz, Gunter ^g   Eiermann, Wolfgang ^h   Neven, Patrick ⁱ   Stierer, Michael ^j   Holcombe, Chris ^k   Coleman, Robert E ^l   Jones, Louise ^b   Ellis, Ian ^m   Cuzick, Jack ^b  

^a UNIVERSITY OF NEWCASTLE   (Australia)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c Genesis Breast Cancer Prevention Centre   (United Kingdom)

^d EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^e MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^f CENTRE FRANÇOIS BACLESSE   (France)

^g German Breast Group   (Germany)

^h Interdisciplinary Oncology Center   (Germany)

ⁱ UNIVERSITY OF LEUVEN   (Belgium)

^j Austrian Breast and Colorectal Cancer Study Group   (Austria)

^k ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

^l WESTON PARK HOSPITAL   (United Kingdom)

^m UNIVERSITY OF NOTTINGHAM   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; HORMONE RECEPTOR; PLACEBO; TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; AROMATASE INHIBITOR; NITRILE; TRIAZOLE DERIVATIVE;

ADULT; ARTICLE; BREAST CANCER; CANCER PREVENTION; CANCER RECURRENCE; CANCER SURGERY; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; EXCISION; FEMALE; FEMALE GENITAL TRACT CANCER; FRACTURE; HUMAN; HYPERCHOLESTEROLEMIA; INTENTION TO TREAT ANALYSIS; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MUSCLE SPASM; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT DURATION; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CLINICAL TRIAL; COMPARATIVE STUDY; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PREVENTION AND CONTROL; TUMOR RECURRENCE;

ADMINISTRATION, ORAL; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INTENTION TO TREAT ANALYSIS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NITRILES; POSTMENOPAUSE; TAMOXIFEN; TRIAZOLES;

EID: 84959482139     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(15)01129-0     Document Type: Article

References (26)

1. A Jemal, F Bray, MM Center et al. Global cancer statistics CA Cancer J Clin 61 2011 69 90
2. K Mokbel, B Cutuli Heterogeneity of ductal carcinoma in situ and its effects on management Lancet Oncol 7 2006 756 765
3. A Francis, J Thomas, L Fallowfield et al. Addressing overtreatment of screen detected DCIS: the LORIS trial Eur J Cancer 51 2015 2296 2303
4. M Worni, I Akushevich, R Greenup et al. Trends in treatment patterns and outcomes for ductal carcinoma in situ J Natl Cancer Inst 107 2015 djv263
5. A Goodwin, S Parker, D Ghersi, N Wilcken Post-operative radiotherapy for ductal carcinoma in situ of the breast Cochrane Database Syst Rev 11 2013 CD000563.
6. D Dodwell, K Clements, G Lawrence et al. Radiotherapy following breast-conserving surgery for screen-detected ductal carcinoma in situ: indications and utilisation in the UK. Interim findings from the Sloane Project Br J Cancer 97 2007 725 729
7. B Fisher, J Dignam, N Wolmark et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial Lancet 353 1999 1993 2000
8. J Cuzick, I Sestak, SE Pinder et al. Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial Lancet Oncol 12 2011 21 29
9. DC Allred, SJ Anderson, S Paik et al. Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24 J Clin Oncol 30 2012 1268 1273
10. RG Margolese, RS Cecchini, TB Julian et al. Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial Lancet 2015 published online Dec 10. http://dx.doi.org/10.1016/S0140-6736(15)01168-X
11. J Cuzick, I Sestak, JF Forbes et al. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial Lancet 383 2014 1041 1048
12. B Fisher, JP Costantino, DL Wickerham et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study J Natl Cancer Inst 90 1998 1371 1388
13. J Cuzick, J Warwick, E Pinney et al. Tamoxifen-induced reduction in mammographic density and breast cancer risk reduction: a nested case-control study J Natl Cancer Inst 103 2011 744 752
14. D Cox Analysis of survival data 1984 Chapman & Hall New York, NY
15. DR Cox Regression models and life tables J R Stat Soc 34 1972 187 220
16. EL Kaplan, P Meier Nonparametric estimation from incomplete observations J Am Stat Assoc 53 1958 457 481
17. J Cuzick, I Sestak, M Baum et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial Lancet Oncol 11 2010 1135 1141
18. A Buzdar, A Howell, J Cuzick et al. Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial Lancet Oncol 7 2006 633 643
19. M Dowsett, C Allred, J Knox et al. Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial J Clin Oncol 26 2008 1059 1065
20. J Cuzick, I Sestak, S Cawthorn et al. Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial Lancet Oncol 16 2015 67 75
21. TJ Powles, S Ashley, A Tidy, IE Smith, M Dowsett Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial J Natl Cancer Inst 99 2007 283 290
22. B Fisher, JP Costantino, CK Redmond et al. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14 J Natl Cancer Inst 86 1994 527 537
23. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials Lancet 365 2005 1687 1717
24. SB Brown, SE Hankinson Endogenous estrogens and the risk of breast, endometrial, and ovarian cancers Steroids 99 2015 8 10
25. Collaborative Group On Epidemiological Studies Of Ovarian Cancer Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies Lancet 385 2015 1835 1842
26. G Rennert, HS Rennert, M Pinchev, O Lavie, SB Gruber Use of hormone replacement therapy and the risk of colorectal cancer J Clin Oncol 27 2009 4542 4547